Schedule II & RFK ·
Peptide industry stakeholders — ranging from compounding pharmacies to research peptide distributors to academic researchers — have responded to RFK Jr.'s agenda with a mix of optimism and caution. Optimism centers on the prospect of expanded regulatory pathways and increased research funding. Caution reflects awareness that RFK Jr.'s personal interest in peptides does not automatically translate into regulatory change, and that changes, if made, may impose new requirements alongside new opportunities. Industry associations have submitted detailed public comments to HHS advocating for specific changes, including 503A bulks list additions, research pathway clarifications, and enforcement priority statements.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.